natgillin/translations-raw huggingface dataset:
Treatment with Valdoxan should only be prescribed after careful consideration of benefit and risk in patients with hepatic injury risk factors e.g. obesity/overweight/non-alcoholic fatty liver disease, diabetes, substantial alcohol intake and in patients receiving concomitant medicinal products associated with risk of hepatic injury.
Zdravljenje z zdravilom Valdoxan lahko predpišete le po skrbnem pretehtanju koristi in tveganja pri bolnikih s prisotnimi dejavniki tveganja za poškodbo jeter, npr. debelost/prekomerna telesna masa/zamaščenost jeter nealkoholnega izvora, sladkorna bolezen, ter bolnikih, ki uživajo znatne količine alkohola ali sočasno jemljejo zdravila, ki jih spremlja tveganje za poškodbe jeter.
Treatment with Vargatef is not recommended in patients with moderate or severe hepatic impairment (see section 4.2).
Zato zdravljenje z zdravilom Vargatef za te bolnike ni priporočljivo (glejte poglavje 4.2).
Treatment with Vargatef may lead to a higher risk of bleeding if you have recently had a surgery or plan to have a surgery.
Zdravljenje z zdravilom Vargatef lahko poveča tveganje za krvavitev; če ste pred kratkim imeli kirurški poseg ali ga načrtujete.
Treatment with Vectibix should be supervised by a doctor who has experience in the use of cancer therapy.
Zdravljenje z zdravilom Vectibix mora nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje rakavih obolenj.
Treatment with Vedrop should be started and supervised by a doctor who has experience in treating patients with congenital or hereditary chronic cholestasis.
Zdravljenje z zdravilom Vedrop mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s kongenitalno ali dedno kronično holestazo.
Treatment with vernakalant, converted 51.7% of patients to SR at 90 minutes versus 5.2% with amiodarone resulting in a significantly faster conversion rate from AF to SR within the first 90 minutes compared to amiodarone (log-rank P-value < 0.0001).
Pri zdravljenju z vernakalantom je prehod v sinusni ritem v obdobju do 90 minut doseglo 51,7 % bolnikov, z amiodaronom pa 5,2 %, pri čemer je pri zdravljenju z vernakalantom značilno hitreje prišlo do prehoda iz atrijske fibrilacije v sinusni ritem v prvih 90 minutah kot pri zdravljenju z amiodaronom (vrednost p z log-rang testom < 0,0001).
Treatment with Victrelis should be initiated and monitored by a physician experienced in the management of chronic hepatitis C.
Zdravljenje z zdravilom Victrelis mora uvesti in spremljati zdravnik z izkušnjami z zdravljenjem kroničnega hepatitisa C.
Treatment with Victrelis should be started and monitored by a doctor experienced in managing chronic hepatitis C.
Zdravljenjem z zdravilom Victrelis mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa C.
Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA- (Homeostasis Model Assessment–), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test.
Zdravljenje z vildagliptinom v odmerkih 50-100 mg dnevno je pri bolnikih s sladkorno boleznijo tipa 2 pomembno izboljšalo vrednosti kazalcev delovanja beta celic, vključno z modelom ocene homeostaze HOMA- (Homeostasis Model Assessment-), razmerjem med proinsulinom in insulinom ter merjenjem odzivnosti beta celic po obroku s pogostim vzorčenjem.
Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA- (Homeostasis Model Assessment–), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test.
Zdravljenje z vildagliptinom v odmerkih 50-100 mg dnevno je pri bolnikih z diabetesom tipa 2 pomembno izboljšalo vrednosti kazalcev delovanja beta celic, vključno z modelom ocene homeostaze HOMA-β, razmerjem med proinsulinom in insulinom ter merjenjem odzivnosti beta celic po obroku s pogostim vzorčenjem.
Treatment with Viread should be started by a doctor who has experience in the treatment of HIV infection or chronic hepatitis B. Viread is taken once a day with food.
Zdravljenje z zdravilom Viread mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV ali kroničnega hepatitisa B. Zdravilo se vzame enkrat na dan skupaj s hrano.
Treatment with Volibris is started at a dose of 5 mg once a day and may be increased to 10 mg daily depending on response and how well the medicine is tolerated.
Zdravljenje z zdravilom Volibris se začne s 5-miligramskim odmerkom enkrat na dan, ki se lahko poveča na 10 mg na dan, odvisno od odziva bolnika in od tega, kako dobro bolnik zdravilo prenaša.
Treatment with Volibris must be started by a doctor who has experience in the treatment of PAH.
Zdravljenje z zdravilom Volibris mora uvesti zdravnik z izkušnjami z zdravljenjem pljučne arterijske hipertenzije.
Treatment with Xadago should be started at 50 mg per day.
Zdravljenje z zdravilom Xadago je treba začeti z odmerkom 50 mg na dan.
Treatment with Xagrid should only be started by a doctor who has experience in the treatment of essential thrombocythaemia.
Zdravljenje z zdravilom Xagrid sme uvesti samo zdravnik, ki ima izkušnje z zdravljenjem esencialne trombocitemije.
Treatment with Xarelto should be continued provided the benefit outweighs the risk of bleeding.
Zdravljenje z zdravilom Xarelto je treba nadaljevati, če koristi odtehtajo tveganje za krvavitve.
Treatment with Xarelto should be started as soon as possible after stabilisation of the acute coronary syndrome, at the earliest 24 hours after admission to hospital and at the time when parenteral (via injection) anticoagulation therapy would normally be stopped.
Zdravljenje z zdravilom Xarelto morate začeti čimprej po stabilizaciji akutnega koronarnega sindroma, najprej 24 ur po sprejemu v bolnišnico in takrat, ko se parenteralno antikoagulacijsko zdravljenje (z injekcijami) običajno ukine.
Treatment with Xarelto should start six to 10 hours after surgery, provided that the patient is no longer bleeding from the site of surgery.
Zdravljenje z zdravilom Xarelto je treba začeti od šest do deset ur po kirurškem posegu, če bolnik iz operiranega mesta ne krvavi več.
Treatment with Xultophy and metformin was compared with treatment using insulin degludec and metformin.
Zdravljenje z zdravilom Xultophy in metforminom so primerjali z zdravljenjem z insulinom degludekom in metforminom.
Treatment with Yervoy should be started and supervised by a specialist doctor experienced in treating cancer.
Zdravljenje z zdravilom Yervoy mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z zdravljenjem raka.
Treatment with Zaltrap should be supervised by a doctor who is experienced in using anticancer medicines.
Zdravljenje z zdravilom Zaltrap mora nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Treatment with Zelboraf should be started and supervised by a specialist doctor experienced in treating cancer.
Zdravljenje z zdravilom Zelboraf mora uvesti in nadzirati zdravnik specialist, ki ima izkušnje z zdravljenjem raka.
Treatment with Zerene should be as short as possible and should last for no more than two weeks.
Zdravljenje z zdravilom Zerene mora biti čim krajše in naj ne traja več kot dva tedna.
Treatment with Zinbryta 150 mg every 4 weeks versus placebo significantly reduced the annualised relapse rate (ARR) and risk of relapse compared to placebo.
Zdravljenje z zdravilom Zinbryta 150 mg vsake 4 tedne v primerjavi s placebom je značilno zmanjšalo letno stopnjo recidivov (ARR - annualised relapse rate) in tveganje za recidiv v primerjavi s placebom.
Treatment with Zinbryta can help to prevent you from getting worse, although it will not cure MS.
Zdravljenje z zdravilom Zinbryta lahko pomaga preprečiti slabšanje bolezni, vendar MS ne ozdravi.
Treatment with Zydelig should be conducted by a physician experienced in the use of anticancer therapies.
Zdravljenje z zdravilom Zydelig mora voditi zdravnik z izkušnjami pri uporabi zdravil proti raku.
Treatment with Zydelig should be withheld in patients while absolute neutrophil count (ANC) is below 500 per mm3.
Zdravljenje z zdravilom Zydelig je treba začasno ustaviti pri bolnikih z absolutnim številom nevtrofilcev (ANC) pod 500 na mm3.
Treatment with ZYTIGA should not be reinitiated until symptoms of the toxicity have resolved to Grade 1 or baseline.
Zdravljenje z zdravilom ZYTIGA se lahko ponovno uvede, ko se simptomi toksičnosti povrnejo na stopnjo 1 ali na izhodiščno vrednost.
Treatment withdrawal may be considered taking into account patient’s disease and past history.
Glede na bolnikovo bolezen in njeno anamnezo je treba premisliti o prekinitvi zdravljenja z zdravilom.
Treatment within 4 weeks with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine.
Zdravljenje znotraj 4 tednov z inhibitorji DPD, vključno s sorivudinom ali kemično podobnimi analogi, kot je brivudin.
Treatment*
Zdravljenje
treatment, and 0.75 (95% CI: 0.45, 1.26) for BRAF mutant with prior BRAF treatment.
0,69 (95 % IZ: 0,33; 1,45) za mutacijo BRAF brez predhodnega zdravljenja BRAF in 0,75 (95 % IZ: 0,45; 1,26) za mutacijo BRAF s predhodnim zdravljenjem BRAF.
Treatment- experienced (n = 69)
Predhodno zdravljeni bolniki (n = 69)
Treatment- experienced (n = 71)
Predhodno zdravljeni bolniki (n = 71)
Treatment- Experienced REYATAZ
Zdravljenje bolnikov, ki so že prejemali kapsule REYATAZ
Treatment- experienced*
Povečanje virusnega bremena med zdravljenjem (“virologic
Treatment- experienced*
Predhodno že zdravljeni
Treatment- related clinical signs were mainly related to sedation, reduced food consumption and secondary changes in body weight, body weight gain and organ weights.
Klinični znaki, povezani z zdravljenjem, so bili povezani predvsem s sedacijo, zmanjšanim uživanjem hrane in sekundarnimi spremembami telesne mase, spremembami pri pridobivanju telesne mase ter s spremembami mase organov.
Treatment-corrected change from baseline in HbA1c (%)† (1-sided CI)
Z zdravilom korigirana sprememba vrednosti HbA1c od izhodišča (%)† (1-stranski IZ)
Treatment-emergent amino acid substitutions in the pooled analysis of Viekirax and dasabuvir with and without RBV regimens in Phase 2b and Phase 3 clinical trials (N=2510)
Med zdravljenjem nastale aminokislinske substitucije v kumulativni analizi shem z zdravilom Viekirax in dasabuvirjem (z RBV ali brez njega) v kliničnih preskušanjih faze 2b in 3 (N = 2510)
Treatment-emergent anti-idarucizumab antibodies with low titers were observed in 4 % (9/224) of the subjects suggesting a low immunogenic potential of idarucizumab.
Iz zdravljenja izvirajoča protitelesa proti idarucizumabu z majhnimi titri so opazili pri 4 % (9/224) preizkušancev, kar kaže na majhen imunogeni potencial idarucizumaba.
Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.
Zaradi jetrnih neželenih učinkov, ki so se pojavili med zdravljenjem, so zdravljenje trajno prekinili pri 50 preiskovancih (21,4 %), ki so prejemali vorikonazol, in 18 preiskovancih (7,1 %), ki so prejemali itrakonazol.
Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.
Zaradi jetrnih neželenih učinkov, ki so se pojavili med zdravljenjem, so zdravljenje trajno prekinili pri 50 preskušancih (21,4 %), ki so prejemali vorikonazol, in 18 preskušancih (7,1 %), ki so prejemali itrakonazol.
Treatment-emergent laboratory abnormalities observed in the placebo-controlled phase III trials are shown in Table 4, 4a and Table 5 (see also section 4.4).
Nenormalni izvidi laboratorijskih preiskav zaradi katerih je bilo potrebno zdravljenje in so jih opazili v s placebom nadzorovanih preskušanjih III. faze so navedeni v preglednicah 4, 4a in 5 (glejte tudi poglavje 4.4).
Treatment-emergent major or APV-associated protease mutations were observed in virus isolated from 2 patients.
Med zdravljenjem nastale pomembne ali z APV- povezane proteazne mutacije so opazili pri virusih, izoliranih od 2 bolnikov.
Treatment-emergent reactions during concomitant and monotherapy treatment phases in patients with newly diagnosed glioblastoma multiforme
Neželeni učinki med sočasnim zdravljenjem in med monoterapijo pri bolnikih z novo diagnosticiranim multiformnim glioblastomom
Treatment-emergent substitutions were detected in both HCV drug targets in 23/37 (62 %) genotype 1a, 1/8 (13 %) genotype 1b and 2/5 (40 %) genotype 4subjects.
Med zdravljenjem nastale substitucije so pri tarčnih molekulah obeh HCV zdravil odkrili pri 23/37 (62 %) preiskovancih z genotipom 1a, 1/8 (13 %) z genotipom 1b in 2/5 (40 %) z genotipom 4.
Treatment-experienced
Predhodno zdravljeni
Treatment-experienced darunavir/cobicistat 800/150 mg once daily
Z izkušnjami z ART darunavir/kobicistat 800/150 mg enkrat na dan + OBR
Treatment-experienced paediatric patients (6 years to less than 18 years of age)
Že zdravljeni pediatrični bolniki (6 let do manj kot 18 let)
Treatment-experienced patients
Predhodno zdravljeni bolniki
Treatment-Experienced Patients by Subgroup
Zdravljeni bolniki po podskupinah
Treatment-experienced patients had failed prior treatment with PEG-IFN + ribavirin ± an HCV protease inhibitor or sofosbuvir + ribavirin ± PEG-IFN.
Pri predhodno zdravljenih bolnikih je bilo predhodno zdravljenje s PEG-IFN + ribavirinom ± zaviralcem proteaze HCV ali sofosbuvirjem + ribavirinom ± PEG-IFN neuspešno.
Treatment-Experienced REYATAZ
Predhodno že zdravljeni bolniki
Treatment-free (3 weeks)
Obdobje brez zdravljenja (3 tedni)
Treatment-naive adult patients
Predhodno še nezdravljeni odrasli bolniki
Treatment-naïve
Predhodno nezdravljeni
Treatment-naïve
Še nezdravljeni
Treatment-naïve (ELECTRONb and PROTONb)
Predhodno nezdravljeni (ELECTRONb in PROTONb)
Treatment-naïve (n = 201)
Predhodno nezdravljeni bolniki (n = 201)
Treatment-naïve (n = 206)
Predhodno nezdravljeni bolniki (n = 206)
Treatment-naïve (NEUTRINO)
Predhodno nezdravljeni (NEUTRINO)
Treatment-naïve (QUANTUMb and 11-1-0258b)
Predhodno nezdravljeni (QUANTUMb in 11-1-0258b)
Treatment-naïve (VALENCE)
Predhodno nezdravljeni (VALENCE)
Treatment-naïve adults in studies GS-US-292-0104 and GS-US-292-0111b
Predhodno nezdravljeni odrasli v študijah GS-US-292-0104 in GS-US-292-0111b
Treatment-naïve adults with or without cirrhosis – ION-1 (study 0102) – Genotype 1
Predhodno nezdravljeni odrasli s cirozo ali brez nje – ION-1 (študija 0102) – genotip 1
Treatment-naïve adults without cirrhosis – ION-3 (study 0108) – Genotype 1
Predhodno nezdravljeni odrasli brez ciroze – ION-3 (študija 0108) – genotip 1
Treatment-naïve and co-infected with HIV (PHOTON-1)
Predhodno nezdravljeni s sočasno okužbo s HIV (PHOTON-1)
Treatment-naïve and peginterferon+ribavirin -experienced, with compensated cirrhosis
Še nezdravljeni in že zdravljeni peginterferonom + ribavirinom, s kompenzirano cirozo
Treatment-naïve and previously treated adults - VALENCE (study 133)
Predhodno nezdravljeni in predhodno zdravljeni odrasli - VALENCE (študija 133)
Treatment-naïve and prior relapse patients2
Bolniki, ki še niso bili zdravljeni ali so po predhodnem zdravljenju ponovno zboleli2
Treatment-naïve and virologically suppressed HIV-1 infected adult patients
Zdravljenje predhodno nezdravljenih odraslih bolnikov z virološko supresijo, okuženih z virusom HIV-1
Treatment-naïve co-infected with HIV (PHOTON-1)
Predhodno nezdravljeni s sočasno okužbo s HIV (PHOTON-1)
Treatment-naïve darunavir/cobicistat 800/150 mg once daily
Brez izkušenj z ART darunavir/kobicistat 800/150 mg enkrat na dan + OBR
Treatment-naïve darunavir/cobicistat 800/150 mg once daily
darunavir/kobicistat 800/150 mg
Treatment-naïve darunavir/cobicistat 800/150 mg once daily+ OBR
Brez izkušenj z ART darunavir/kobicistat 800/150 mg enkrat na dan + OBR
Treatment-naïve HIV-1 infected adult patients
Odrasli bolniki, okuženi s HIV-1, ki predhodno niso prejemali protiretrovirusnih zdravil
Treatment-naïve HIV-1 infected adult patients
Predhodno nezdravljeni odrasli bolniki, okuženi z virusom HIV-1
Treatment-naïve HIV-1 infected patients
Predhodno nezdravljeni bolniki, okuženi s HIV-1
Treatment-naïve N=101
Virusni neodziv
Treatment-naïve patient population
Populacija predhodno nezdravljenih bolnikov
Treatment-naïve patients
Bolniki, ki prej še niso bili zdravljeni
Treatment-naïve patients
Nezdravljeni bolniki
Treatment-naïve patients
Predhodno nezdravljeni bolniki
Treatment-naïve patients
Prvič zdravljeni bolniki
treatment-naïve patients such events occurred at a similarly low rate with maraviroc and control (efavirenz).
Med še nezdravljenimi bolniki je bil delež takšnih dogodkov z maravirokom podobno majhen kot s primerjalnim zdravilom (efavirenz).
treatment-naïve treatment-experienced1
predhodno nezdravljeni predhodno zdravljeni1
treatment-naïve treatment-experienced2
predhodno nezdravljeni predhodno zdravljeni2
treatment-naïve treatment-experienced4
predhodno nezdravljeni predhodno zdravljeni4
Treatment-naïve With RBV
Še nezdravljeni Z RBV
Treatment-naïve, without cirrhosis
Še nezdravljeni, brez ciroze
Treatment-naïvea (NEUTRINO)
Predhodno nezdravljenia (NEUTRINO)
Treatment-related serious adverse events (TRSAEs) were reported in 23.7% of patients receiving sunitinib and in 6.9% of patients receiving IFN-α.
O resnih neželenih učinkih, povezanih z zdravljenjem (TRSAEs – treatment-related serious adverse events), so poročali pri 23,7 % bolnikov, ki so prejemali sunitinib in pri 6,9 % bolnikov, ki so prejemali IFN-.
Treatment-related venous thromboembolic events were reported in approximately 1.0% of patients with solid tumours who received sunitinib on clinical trials, including GIST and MRCC.
Z zdravljenjem povezane venske trombembolične dogodke so zabeležili pri približno 1,0 % bolnikov s čvrstimi tumorji, ki so prejemali sunitinib v kliničnih preskušanjih, vključno z GIST in MRCC.
Treatment:
Zdravljenje
Treatment: In the event of overdose, treatment should be symptomatic.
Zdravljenje: Pri prevelikem odmerjanju je potrebno simptomatično zdravljenje.
Treatment: In the event of overdose, treatment should be symptomatic.
Zdravljenje: Pri prevelikem odmerku je potrebno simptomatsko zdravljenje.
Treatment: INTELENCE vs. placebo, in addition to a background regimen including darunavir/ritonavir (DRV/rtv), investigator-selected N(t)RTIs and optional enfuvirtide (ENF).
Zdravljenje: zdravilo INTELENCE v primerjavi s placebom, poleg osnovne sheme (BR - background regimen) z darunavirjem/ritonavirjem (DRV/rtv), N(t)RTI, ki jih izbere raziskovalec, in enfuvirtidom (ENF) po izbiri.
Treatment: Telmisartan is not removed by haemodialysis.
Zdravljenje: Telmisartan se s hemodializo ne odstrani.
Treatment: The recommended treatment dose for infants 0 - 12 months of age is 3 mg/kg twice daily.
Zdravljenje:Priporočeni odmerek za zdravljenje dojenčkov, starih od 0 do 12 mesecev, je 3 mg/kg dvakrat na dan.
Treatment: treatment naïve: Viekirax without ribavirin or with weight-based ribavirin for 12 weeks pegIFN + RBV experienced: Viekirax with weight-based ribavirin for 12 weeks
Zdravljenje: še nezdravljeni: Viekirax brez ribavirina ali z ribavirinom, odvisnim od telesne mase, 12 tednov že zdravljeni s kombinacijo pegIFN + RBV: Viekirax z ribavirinom, odvisnim od telesne mase, 12 tednov
Treatment: Viekirax and dasabuvir with investigator chosen ribavirin dose for 24 weeks
Zdravljenje: Viekirax in dasabuvir z odmerkom ribavirina, ki ga izbere raziskovalec, 24 tednov
Treatment: Viekirax and dasabuvir with weight-based ribavirin for 12 or 24 weeks
Zdravljenje: Viekirax in dasabuvir z ribavirinom, odvisnim od telesne mase, 12 ali 24 tednov
Treatment: Viekirax and dasabuvir without ribavirin or with weight-based ribavirin for 12 weeks
Zdravljenje: Viekirax in dasabuvir brez ribavirina ali z ribavirinom, odvisnim od telesne mase, 12 tednov
Treatments could also be discontinued at the time of confirmed radiographic progression at the discretion of the investigator.
Zdravljenje so lahko prekinili tudi ob potrditvi radiološko potrjenega napredovanja bolezni.
Treatments should only be initiated when menstruation has occurred:
Cikli se smejo začeti samo ob nastopu menstruacije:
Treatments should only be initiated when menstruation has occurred: the first treatment course should start during the first week of menstruation, re-treatment courses should start at the earliest during the first week of the second menstruation following the previous treatment course completion.
Cikli se smejo začeti samo ob nastopu menstruacije: prvi cikel zdravljenja se mora začeti v prvem tednu menstruacije in ponovna zdravljenja se lahko začnejo šele v prvem tednu druge menstruacije po zaključenem prejšnjem ciklu zdravljenja.
Tredaptive (1000 mg/20 mg to 2000 mg/40 mg at week 5)
Tredaptive (1.000 mg/20 mg do 2.000 mg/40 mg 5. teden)
Tredaptive 1,000 mg/20 mg modified-release tablets Nicotinic acid/laropiprant
Tredaptive 1.000 mg/20 mg tablete s prirejenim sproščanjem nikotinska kislina/laropiprant
Tredaptive 1,000 mg/20 mg modified-release tablets.
Tredaptive 1.000 mg/20 mg tablete s prirejenim sproščanjem
Tredaptive 1000 mg/20 mg modified-release tablets Nicotinic acid/laropiprant
Tredaptive 1.000 mg/20 mg tablete s prirejenim sproščanjem nikotinska kislina/laropiprant
Tredaptive is not recommended in pregnancy unless clearly necessary.
Zdravila Tredaptive v nosečnosti ne priporočamo, razen če je nujno potrebno.
Tredaptive is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly ‘combined mixed dyslipidaemia’ and ‘primary hypercholesterolaemia’.
Zdravilo Tredaptive se uporablja kot dodatek k prehrani in telesni vadbi pri bolnikih z dislipidemijo (nenormalno visoka raven maščobe v krvi), zlasti pri tistih s kombinirano mešano dislipidemijo in primarno hiperholesterolemijo.
Tredaptive is used in addition to diet to lower your ‘bad’ cholesterol level.
Zdravilo Tredaptive se uporablja poleg diete za: znižanje "slabega" holesterola.
Tredaptive was consistently efficacious across all prespecified patient subpopulations defined by race, gender, baseline LDL-C, HDL-C and TG levels, age and diabetes status.
Tredaptive je bil enako učinkovit v vseh skupinah populacije bolnikov, ne glede na raso, spol, izhodiščno koncentracijo hLDL, hHDL in trigliceridov, ali glede na starost, pa tudi v skupini sladkornih bolnikov.
Tredaptive: No studies have been performed in paediatric patients.
Tredaptive: Študij pri pediatričnih bolnikih niso izvedli.
Tredaptive: Use in patients with hepatic insufficiency has not been studied.
Tredaptive: Uporaba pri bolnikih z jetrno insuficienco ni raziskana.
Tredaptive: Use in patients with renal insufficiency has not been studied.
Tredaptive: Uporaba pri bolnikih z ledvično insuficienco ni raziskana.
Tredegar, NP22 3AA United Kingdom
Tredegar, NP22 3AA Velika Britanija
Trehalose Calcium chloride Albumin Sodium chloride Sodium citrate
trehaloza kalcijev klorid albumin natrijev klorid natrijev citrat
Trehalose Calcium chloride Human Albumin Sodium chloride Sodium citrate
trehaloza kalcijev klorid humani albumin natrijev klorid natrijev citrat
Trehalose dihydrate L-histidine
trehaloza dihidrat L-histidin
Trehalose dihydrate Sodium phosphate Polysorbate 20 Water for injections
trehaloza dihidrat natrijev fosfat polisorbat 20 voda za injekcije
trembling
tresenje
Trembling or feeling confused
Tresenje ali občutek zmedenosti
Trembling or feeling confused
tresenje ali občutek zmedenosti,
trembling,
drgetanje,
Trembling,
tresenje,
trembling, headache
tresenje, glavobol
Trembling, headache
tresenje, glavobol,
trembling, loss of sensation, burning or prickling sensation
tresavica, izguba čutov, pekoč občutek ali ščemenje
trembling, sensation of spinning head (vertigo), dizziness
tresenje, občutek vrtenja v glavi (vrtoglavica), omotica
trembling, sweating, looking pale a change in mood or feeling anxious or confused.
tresenje, znojenje, bledica sprememba razpoloženja ali občutek tesnobe ali zmedenosti